Document:

Exhibit
10.4

  

PRIVATE
PLACEMENT WARRANTS SUBSCRIPTION AGREEMENT

 

THIS
PRIVATE PLACEMENT WARRANTS SUBSCRIPTION AGREEMENT, dated as of December 22, 2020 (as it may from time to time be amended and including
all exhibits referenced herein, this “Agreement”), is entered into by and between Viveon Health Acquisition
Corp., a Delaware corporation (the “Company”) and Viveon Health, LLC, a Delaware limited liability company
(the “Purchaser”).

 

WHEREAS, the Company intends
to consummate an initial public offering of the Company’s units (the “Public Offering”), each comprised
of one share of the Company’s common stock, par value $0.0001 per share (“Common Stock”), one redeemable warrant
and one right. Each right (“Right”) entitles the holder thereof to receive one-twentieth (1/20) of a share of Common
Stock upon consummation of the Company’s initial business combination. Each warrant entitles the holder to purchase one-half
(1/2) of a share of Common Stock at a price of $11.50 per whole share (subject to adjustment). The Purchaser has agreed to purchase
an aggregate of 18,000,000 warrants (regardless of whether the over-allotment
option in connection with the Public Offering is exercised in full or not) (the “Private Placement Warrants”),
each Private Placement Warrant entitling the holder to purchase one-half (1/2) Share at an exercise price of $11.50 per whole
Share (subject to adjustment).

 

NOW
THEREFORE, in consideration of the mutual promises contained in this Agreement and other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the parties to this Agreement hereby, intending legally to be bound,
agree as follows:

 

AGREEMENT

 

Section
1. Authorization, Purchase and Sale; Terms of the Private Placement Warrants.

 

A. Authorization
of the Private Placement Warrants. The Company has duly authorized the issuance and sale of the Private Placement Warrants
to the Purchaser.

 

B. Purchase and
Sale of the Private Placement Warrants. On the date of the consummation of the Public Offering, and concurrently with the
consummation thereof, or on such earlier time and date as may be mutually agreed by the Purchaser and the Company (the “Closing
Date”), the Company shall issue and sell to the Purchaser, and the Purchaser shall purchase from the Company 18,000,000
Private Placement Warrants at a price of $.50 per warrant for an aggregate purchase price of $9,000,000 (the “Purchase
Price”), which shall be paid by wire transfer of immediately available funds to the Company in accordance with the Company’s
wiring instructions. On the Closing Date, upon payment by the Purchaser of the Purchase Price, the Company, shall either, at its
option, deliver a certificate evidencing the Private Placement Warrants purchased by the Purchaser on such date duly registered
in the Purchaser’s name to the Purchaser, or effect such delivery in book-entry form.

 

     

    

    

 

C. Terms
of the Private Placement Warrants.

 

(i)
The Private Placement Warrants shall have their terms set forth in a warrant agreement to be entered into by the Company and a
warrant agent, in connection with the Public Offering (the “Warrant Agreement”).

 

(ii)
At or prior to the time of the Closing Date, the Company and the Purchaser shall enter into a registration rights agreement
(the “Registration Rights Agreement”) pursuant to which the Company will grant certain registration rights
to the Purchaser relating to the Private Placement Warrants and the Shares underlying the Private Placement Warrants.

 

D.
Restrictions on Transfer. Until the consummation of a Business Combination, the only permitted
transfers of the Private Placement Warrants will be (i) to officers, directors, consultants or affiliates of the Purchaser or the
Company, (ii) to the Purchaser’s stockholders, partners or members upon such Purchaser’s liquidation, (iii) by bona
fide gift to an immediate family member of the Purchaser’s members or to a trust, the beneficiary of which is the Purchaser
or an immediate family member of the Purchaser’s members for estate planning purposes, (iv) by virtue of the laws of descent
and distribution upon death of a member of the Purchaser, (v) pursuant to a qualified domestic relations order binding on a member
of the Purchaser, (vi) to the Company for no value for cancellation in connection with the consummation of a Business Combination,
(vii) by private sales of the Private Placement Warrants made at or prior to the consummation of a Business Combination at prices
no greater than the price at which the Private Placement Warrants were originally purchased, or (viii) by private sales of the
Private Placement Warrants in connection with the consummation of our initial Business Combination; provided, however, that except
for clause (vi) or with the Company’s prior written consent, such permitted transfers may be implemented only upon the respective
transferee’s written agreement to be bound by the terms and conditions of this Agreement and of the Insider Letter signed
by the Purchaser transferring the shares.  As used herein, the term “Business Combination” shall mean any acquisition
by share exchange, share reconstruction and amalgamation with, purchasing all or substantially all of the assets of, entering into
contractual arrangements with, or engaging in any other similar business combination with one or more businesses or entities by
the Company.

 

Section
2. Representations and Warranties of the Company. As a material inducement to the Purchaser to enter into this Agreement
and purchase the Private Placement Warrants, the Company hereby represents and warrants to the Purchaser (which representations
and warranties shall survive the Closing Date) that:

 

A. Organization
and Corporate Power. The Company is a corporation duly organized, validly existing and in good standing under the laws of
the State of Delaware and is qualified to do business in every jurisdiction in which the failure to so qualify would reasonably
be expected to have a material adverse effect on the financial condition, operating results or assets of the Company. The Company
possesses all requisite corporate power and authority necessary to carry out the transactions contemplated by this Agreement and
the Warrant Agreement.

 

B. Authorization;
No Breach.

 

(i)
The execution, delivery and performance of this Agreement and the Private Placement Warrants have been duly authorized and approved
by the Company as of the Closing Date. This Agreement constitutes a valid and binding obligation of the Company, enforceable
in accordance with its terms. Upon issuance in accordance with, and payment pursuant to, the terms of the Warrant Agreement and
this Agreement, the Private Placement Warrants will constitute valid and binding obligations of the Company, enforceable in accordance
with their terms.

 

    2

    

    

 

(ii)
The execution and delivery by the Company of this Agreement and the Private Placement Warrants, the issuance and sale of the
Private Placement Warrants, the issuance of the Shares upon exercise of the Private Placement Warrants and the fulfillment
of, and compliance with, the respective terms hereof and thereof by the Company, do not and will not as of the Closing Date
(a) conflict with or result in a breach of the terms, conditions or provisions of, (b) constitute a default under, (c) result
in the creation of any lien, security interest, charge or encumbrance upon the Company’s capital stock or assets under,
(d) result in a violation of, or (e) require any authorization, consent, approval, exemption, action, notice, declaration or
filing, in each case, by or to any court or administrative or governmental body or agency pursuant to the certificate of
incorporation or the bylaws of the Company (in effect on the date hereof or as may be amended prior to completion of the
contemplated Public Offering), or any material law, statute, rule or regulation to which the Company is subject, or any
agreement, order, judgment or decree to which the Company is subject, except for any filings required after the date hereof
under federal or state securities laws.

 

C. Title
to Securities. Upon issuance in accordance with, and payment pursuant to, the terms hereof and the Warrant Agreement, the
Placement Warrants will be duly and validly issued and the Shares issuable upon exercise of the Private Placement Warrants will
be duly and validly issued, fully paid and nonassessable. On the date of issuance of the Placement Warrants, the Shares issuable
upon exercise of the Private Placement Warrants shall have been reserved for issuance. Upon issuance in accordance with, and payment
pursuant to, the terms hereof and the Warrant Agreement, the Purchaser will have good title to the Private Placement Warrants
and the Shares issuable upon exercise of such Private Placement Warrants, free and clear of all liens, claims and encumbrances
of any kind, other than (i) transfer restrictions hereunder and under the other agreements contemplated hereby, (ii) transfer
restrictions under federal and state securities laws, and (iii) liens, claims or encumbrances imposed due to the actions of the
Purchaser.

 

D. Valid
Issuance. The total number of shares of all classes of capital stock which the Company has authority to issue is 61,000,000
shares of stock (which consists of 60,000,000 shares of Common Stock, and 1,000,000 shares of preferred stock, par value
$0.0001 per share (“Preferred Stock”). As of the date hereof, the Company has issued and outstanding 5,031,250 of
Common Stock (of which up to 656,250 shares are subject to forfeiture as described in the Prospectus (File No. 333-251112)
filed pursuant to Rule 424(b)(4) by the Company in connection with the Public Offering) and no shares of Preferred Stock. All
of the issued shares of capital stock of the Company have been duly authorized, validly issued, and are fully paid and
non-assessable.

 

E. Governmental
Consents. No permit, consent, approval or authorization of, or declaration to or filing with, any governmental authority is
required in connection with the execution, delivery and performance by the Company of this Agreement or the consummation by the
Company of any other transactions contemplated hereby.

 

    3

    

    

 

Section
3. Representations and Warranties of the Purchaser. As a material inducement to the Company to enter into this Agreement
and issue and sell the Private Placement Warrants to the Purchaser, the Purchaser hereby represents and warrants to the Company
(which representations and warranties shall survive the Closing Date) that:

 

A. Organization
and Requisite Authority. The Purchaser possesses all requisite power and authority necessary to carry out the transactions
contemplated by this Agreement.

 

B. Authorization;
No Breach.

 

(i)
This Agreement constitutes a valid and binding obligation of the Purchaser, enforceable in accordance with its terms, subject
to bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other laws of general applicability relating
to or affecting creditors’ rights and to general equitable principles (whether considered in a proceeding in equity or law).

 

(ii)
The execution and delivery by the Purchaser of this Agreement and the fulfillment of and compliance with the terms hereof by
the Purchaser does not and shall not as of the Closing Date conflict with or result in a breach by the Purchaser of the
terms, conditions or provisions of any agreement, instrument, order, judgment or decree to which the Purchaser is subject
that would materially impact its ability to perform its obligations hereunder.

 

C. Investment
Representations.

 

(i)
The Purchaser is acquiring the Private Placement Warrants and, upon exercise of the Private Placement Warrants, the Shares issuable
upon such exercise (collectively, the “Securities”), for the Purchaser’s own account, for investment
purposes only and not with a view towards, or for resale in connection with, any public sale or distribution thereof.

 

(ii)
The Purchaser is an “accredited investor” as such term is defined in Rule 501(a)(3) of Regulation D under the Securities
Act of 1933, as amended (the “Securities Act”).

 

(iii)
The Purchaser understands that the Securities are being offered and will be sold to it in reliance on specific exemptions from
the registration requirements of the United States federal and state securities laws and that the Company is relying upon the
truth and accuracy of, and the Purchaser’s compliance with, the representations and warranties of the Purchaser set forth
herein in order to determine the availability of such exemptions and the eligibility of the Purchaser to acquire such Securities.

 

(iv)
The Purchaser did not enter into this Agreement as a result of any general solicitation or general advertising within the meaning
of Rule 502(c) under the Securities Act.

 

(v)
The Purchaser has been furnished with all materials relating to the business, finances and operations of the Company and materials
relating to the offer and sale of the Securities which have been requested by the Purchaser. The Purchaser has been afforded the
opportunity to ask questions of the executive officers and directors of the Company. The Purchaser understands that its investment
in the Securities involves a high degree of risk and it has sought such accounting, legal and tax advice as it has considered
necessary to make an informed investment decision with respect to the acquisition of the Securities.

 

    4

    

    

 

(vi)
The Purchaser understands that no United States federal or state agency or any other government or governmental agency has passed
on or made any recommendation or endorsement of the Securities or the fairness or suitability of the investment in the Securities
by the Purchaser nor have such authorities passed upon or endorsed the merits of the offering of the Securities. 

 

(vii)
The Purchaser understands that: (a) the Securities have not been and are not being registered under the Securities Act or any
state securities laws, and may not be offered for sale, sold, assigned or transferred unless (1) subsequently registered thereunder
or (2) sold in reliance on an exemption therefrom; and (b) except as specifically set forth in the Registration Rights Agreement,
neither the Company nor any other person is under any obligation to register the Securities under the Securities Act or any state
securities laws or to comply with the terms and conditions of any exemption thereunder. While such Purchaser understands that
Rule 144 under the Securities Act is not available for the resale of securities initially issued by shell companies (other than
business combination related shell companies) or issuers that have been at any time previously a shell company, such Purchaser
understands that Rule 144 includes an exception to this prohibition if the following conditions are met: (i) the issuer of the
securities that was formerly a shell company has ceased to be a shell company; (ii) the issuer of the securities is subject to
the reporting requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”);
(iii) the issuer of the securities has filed all Exchange Act reports and material required to be filed, as applicable, during
the preceding 12 months (or such shorter period that the issuer was required to file such reports and materials), other than Form
8-K reports; and (iv) at least one year has elapsed from the time that the issuer filed current Form 10 type information with
the SEC reflecting its status as an entity that is not a shell company.

 

(viii)
The Purchaser understands the high degree of risk associated with investments in the securities of companies in the development
stage such as the Company, has such knowledge and experience in financial and business matters to be able to evaluate the merits
and risks of an investment in the Securities and is able to bear the economic risk of an investment in the Securities in the amount
contemplated hereunder for an indefinite period of time. The Purchaser has adequate means of providing for its current financial
needs and contingencies and will have no current or anticipated future needs for liquidity which would be jeopardized by the investment
in the Securities. The Purchaser can afford a complete loss of its investment in the Securities.

 

Section
4. Conditions of the Purchaser’s Obligations. The obligations of the Purchaser to purchase and pay for the
Private Placement Warrants are subject to the fulfillment, on or before the Closing Date, of each of the following
conditions:

 

A. Representations
and Warranties. The representations and warranties of the Company contained in Section 2 shall be true and correct at and
as of the Closing Date as though then made.

 

    5

    

    

 

B. Performance.
The Company shall have performed and complied with all agreements, obligations and conditions contained in this Agreement that
are required to be performed or complied with by it on or before  the Closing Date.

 

C. No
Injunction. No litigation, statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted,
entered, promulgated or endorsed by or in any court or governmental authority of competent jurisdiction or any self-regulatory
organization having authority over the matters contemplated hereby, which prohibits the consummation of any of the transactions
contemplated by this Agreement or the Warrant Agreement.

 

D. Warrant
Agreement and Registration Rights Agreement. The Company shall have entered into the Warrant Agreement and the Registration
Rights Agreement, each on terms satisfactory to the Purchaser.

 

E. Corporate
Consents. The Company shall have obtained the consent of its Board of Directors authorizing the execution, delivery and performance
of this Agreement and the Warrant Agreement and the issuance and sale of the Private Placement Warrants hereunder.

 

Section
5. Conditions of the Company’s Obligations. The obligations of the Company to the Purchaser under this Agreement
are subject to the fulfillment, on or before  the Closing Date, of each of the following conditions:

 

A. Representations
and Warranties. The representations and warranties of the Purchaser contained in Section 3 shall be true and correct at and
as of  the Closing Date as though then made.

 

B. Performance.
The Purchaser shall have performed and complied with all agreements, obligations and conditions contained in this Agreement that
are required to be performed or complied with by the Purchaser on or before  the Closing Date.

 

C. Corporate
Consents. The Company shall have obtained the consent of its Board of Directors authorizing the execution, delivery and performance
of this Agreement and the Warrant Agreement and the issuance and sale of the Private Placement Warrants hereunder.

 

D. No
Injunction. No litigation, statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted,
entered, promulgated or endorsed by or in any court or governmental authority of competent jurisdiction or any self-regulatory
organization having authority over the matters contemplated hereby, which prohibits the consummation of any of the transactions
contemplated by this Agreement or the Warrant Agreement.

 

E. Warrant
Agreement. The Company shall have entered into the Warrant Agreement on terms satisfactory to the Company.

 

Section
6. Termination. This Agreement may be terminated at any time after January 15, 2021 upon the election by either the
Company or the Purchaser upon written notice to the other party if the closing of the Public Offering does not occur prior to
such date.

 

    6

    

    

 

Section
7. Survival of Representations and Warranties. All of the representations and warranties contained herein shall survive
the Closing Date.

 

Section
8. Definitions. Terms used but not otherwise defined in this Agreement shall have the meaning assigned to such terms
in the registration statement on Form S-1 that the Company has filed with the Securities and Exchange Commission under the Securities
Act in connection with the Public Offering.

 

Section
9. Miscellaneous.

 

A. Successors
and Assigns. Except as otherwise expressly provided herein, all covenants and agreements contained in this Agreement by or
on behalf of any of the parties hereto shall bind and inure to the benefit of the respective successors of the parties hereto
whether so expressed or not. Notwithstanding the foregoing or anything to the contrary herein, the parties may not assign this
Agreement without the prior written consent of the other party hereto, other than assignments by the Purchaser to affiliates thereof
(including, without limitation, one or more of its members).

 

B. Severability.
Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision shall
be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of this Agreement.

 

C. Counterparts.
This Agreement may be executed simultaneously in two or more counterparts, none of which needs to contain the signatures of more
than one party, but all such counterparts taken together shall constitute one and the same agreement. In the event that any signature
is delivered by facsimile transmission or by e-mail delivery of a “pdf” format data file, such signature shall create
a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and
effect as if such facsimile or “.pdf” signature page were an original thereof.

 

D. Descriptive
Headings; Interpretation. The descriptive headings of this Agreement are inserted for convenience only and do not constitute
a substantive part of this Agreement. The use of the word “including” in this Agreement shall be by way of example
rather than by limitation.

 

E. Governing
Law. This Agreement shall be deemed to be a contract made under the laws of the State of New York and for all purposes shall
be construed in accordance with the internal laws of the State of New York without regard to the conflicts of laws principles
thereof.

 

F. Amendments.
This Agreement may not be amended, modified or waived as to any particular provision, except by a written instrument executed
by all parties hereto.

 

[Signature
Page Follows]

 

    7

    

    

 

IN WITNESS WHEREOF,
the parties hereto have executed this Agreement to be effective as of the date first set forth above.

 

	 	COMPANY:
	 	 
	 	VIVEON
    HEALTH ACQUISITION CORP.
	 	 	 
	 	By:	/s/
    Jagi Gill
	 	Name:	Jagi Gill
	 	Title:	Chief Executive
    Officer
	 	 	 
	 	PURCHASER:
	 	 
	 	VIVEON
    HEALTH, LLC  
	 	 	 
	 	By:	/s/
    Romilos Papadopoulos
	 	Name:	Romilos Papadopoulos
	 	Title:	Managing
Member

 

[Signature
Page to Private Placement Warrants Subscription Agreement]

 

 

8Exhibit 10.5

 

STOCK
ESCROW AGREEMENT

 

STOCK ESCROW AGREEMENT,
dated as of December 22, 2020 (“Agreement”), by and among Viveon Health Acquisition Corp., a Delaware corporation (“Company”),
the stockholders of the Company listed on Exhibit A hereto (the “Founders”) and Continental Stock Transfer & Trust
Company, a New York limited purpose trust company (“Escrow Agent”).

 

WHEREAS,
the Company was formed for the purpose of completing a merger, stock exchange, asset acquisition, stock purchase, recapitalization,
reorganization or other similar business combination (a “Business Combination”) with one or more businesses or entities.

 

WHEREAS, the Company
has entered into an Underwriting Agreement, dated December 22, 2020 (“Underwriting Agreement”), with Chardan Capital
Markets LLC (the “Representative”) acting as representative of the several underwriters (collectively, the “Underwriters”),
pursuant to which, among other matters, the Underwriters have agreed to purchase 17,500,000 units (“Units”) of the
Company, plus up to an additional 2,625,000 Units if the Representative exercises the over-allotment option in full. Each Unit
consists of one share of the Company’s common stock, par value $0.0001 per share (“Common Stock”), one redeemable
warrant and one right. Each right (“Right”) entitles the holder thereof to receive one-twentieth (1/20) of a share
of Common Stock upon consummation of the Company’s initial Business Combination. Each warrant entitles the holder to purchase
one-half (1/2) of a share of Common Stock at a price of $11.50 per whole share subject to adjustment, all as more fully described
in the Company’s final Prospectus, dated December 22, 2020 (“Prospectus”) comprising part of the Company’s
Registration Statement on Form S-1, File No. 333-251112 (“Registration Statement”), filed with the Securities and Exchange
Commission, under the Securities Act of 1933, as amended, declared effective on December 22, 2020 (“Effective Date”).

 

WHEREAS,
the Founders have agreed as a condition of the sale of the Units to deposit their shares of Common Stock of the Company in escrow
as hereinafter provided.

 

WHEREAS,
the Company and the Founders desire that the Escrow Agent accept the shares of Common Stock, in escrow, to be held and disbursed
as hereinafter provided.

 

IT
IS AGREED:

 

1. Appointment
of Escrow Agent. The Company and the Founders hereby appoint the Escrow Agent to act in accordance with and subject to the
terms of this Agreement and the Escrow Agent hereby accepts such appointment and agrees to act in accordance with and subject
to such terms.

 

2. Deposit
of Shares. On or before the Effective Date, the Founders’ respective shares of Common Stock set forth on Exhibit A hereto
shall be deposited in escrow, to be held and disbursed subject to the terms and conditions of this Agreement. The Founders acknowledge
that the shares deposited in escrow will be legended to reflect the deposit of such shares under this Agreement.

 

3. Disbursement
of the Escrow Shares.

 

3.1 (a) If the over-allotment option to
purchase all or a portion of the additional 2,625,000 Units of the Company is not exercised in full within 45 days of the date
of the Prospectus (as described in the Underwriting Agreement), the Founders agree that the Escrow Agent shall return to the Company
for cancellation, at no cost, the number of shares of Common Stock determined by multiplying 656,250 by a fraction, (i) the numerator
of which is 2,625,000 minus the number of shares of Common Stock included in the Units purchased by the Underwriters upon the exercise
of the over-allotment option, and (ii) the denominator of which is 2,625,000. The Company shall promptly provide notice to the
Escrow Agent of the expiration or termination of the over-allotment option and the number of Units, if any, purchased by the Underwriters
in connection with the exercise thereof.

 

     

     

    

 

(b) The Founders agree that the Escrow
Agent shall return to the Company for cancellation, at no cost, up to 1,006,250 Escrow Shares (or 875,000 Escrow Shares to the
extent that the underwriters’ over-allotment is not exercised, pro rata) to the extent that Rights are exercised upon the
consummation of an initial Business Combination, as described in the Prospectus.

 

3.2
Except as otherwise set forth herein, the Escrow Agent shall hold the shares remaining after any cancellation required pursuant
to Section 3.1 above (such remaining shares to be referred to herein as the “Escrow Shares”) until (i) with respect
to 50% of the Escrow Shares, the earlier of six months after the date of the consummation of an initial Business Combination,
and the date on which the closing price of the Common Stock equals or exceeds $12.50 per share (as adjusted for stock splits,
stock dividends, reorganizations and recapitalizations) for any 20 trading days within any 30-trading day period following the
consummation of the Business Combination, and (ii) with respect to the remaining 50% of the Escrow Shares, six months after the
date of the consummation of an initial Business Combination or (iii) earlier, in either case if, after the consummation of an
initial Business Combination, there is a consummation of a liquidation, merger, stock exchange or other similar transaction which
results in all of the Company’s stockholders having the right to exchange their shares of common stock for cash, securities,
or other property (such period of time during which the Escrow Shares are held in escrow, the “Escrow Period”). Upon
the achievement of any of the conditions set forth above, the Company shall promptly provide notice to the Escrow Agent, in form
reasonably acceptable to the Escrow Agent. Upon completion of the Escrow Period, the Escrow Agent shall disburse such amount of
each Founder’s Escrow Shares to the applicable Founder. The Escrow Agent shall have no further duties hereunder after the
disbursement of the Escrow Shares in accordance with this Section 3.2.

 

3.3 Notwithstanding
the provisions of Section 3.2, if the Escrow Agent is notified by the Company pursuant to Section 6.7 hereof that the Company’s
Trust Account (as defined in that certain Investment Management Trust Agreement, dated as of the date hereof, by and between the
Company and the Escrow Agent as trustee thereunder) is being liquidated, then the Escrow Agent shall deliver the certificates
representing the Escrow Shares to the Founders promptly after the public stockholders are paid the liquidating distributions and
shall have no further duties hereunder.

 

4. Rights
of Founders in Escrow Shares.

 

4.1 Voting
Rights as a Stockholder. Subject to the terms of the Insider Letters described in Section 4.4 hereof and except as herein
provided, the Founders shall retain all of their rights as stockholders of the Company as long as any shares are held in escrow
pursuant to this Agreement, including, without limitation, the right to vote such shares.

 

4.2 Dividends
and Other Distributions in Respect of the Escrow Shares. For as long as any shares are held in escrow pursuant to this Agreement,
all dividends payable in cash with respect to the Escrow Shares shall be paid to the Founders, but all dividends payable in stock
or other non-cash property (“Non-Cash Dividends”) shall be delivered to the Escrow Agent to hold in accordance with
the terms hereof. As used herein, the term “Escrow Shares” shall be deemed to include the Non-Cash Dividends distributed
thereon, if any.

 

4.3 Restrictions
on Transfer. During the Escrow Period, the only permitted transfers of the Escrow Shares will be (i) to officers, directors,
consultants or affiliates of the Founders or the Company, (ii) to a Founder’s stockholders, partners or members upon such
Founder’s liquidation, (iii) by bona fide gift to a member of the Founders’ immediate family or to a trust, the beneficiary
of which is a Founder or a member of a Founder’s immediate family for estate planning purposes, (iv) by virtue of the laws
of descent and distribution upon death of a Founder, (v) pursuant to a qualified domestic relations order binding on a Founder,
(vi) to the Company for no value for cancellation in connection with the consummation of a Business Combination (vii) by private
sales of the Escrow Shares made at or prior to the consummation of a Business Combination at prices no greater than the price
at which the Escrow Shares were originally purchased or (viii) by private sales in connection with the consummation of our initial
Business Combination; provided, however, that except for clause (vi) or with the Company’s prior written consent, such permitted
transfers may be implemented only upon the respective transferee’s written agreement to be bound by the terms and conditions
of this Agreement and of the Insider Letter signed by the Founder transferring the shares.

 

4.4 Insider
Letters. The Founders have executed letter agreements with the Company and the Representative, dated as of the date hereto,
the form of which is filed as an exhibit to the Registration Statement (“Insider Letter”), respecting the rights and
obligations of such Founders in certain events, including, but not limited to, the liquidation of the Company.

 

    	 	2	 

     

    

 

5. Concerning
the Escrow Agent.

 

5.1 Good
Faith Reliance. The Escrow Agent shall not be liable for any action taken or omitted by it in good faith and in the exercise
of its own best judgment, and may rely conclusively and shall be protected in acting upon any order, notice, demand, certificate,
opinion or advice of counsel (including counsel chosen by the Escrow Agent), statement, instrument, report or other paper or document
(not only as to its due execution and the validity and effectiveness of its provisions, but also as to the truth and acceptability
of any information therein contained) which is believed by the Escrow Agent in good faith to be genuine and to be signed or presented
by the proper person or persons. The Escrow Agent shall not be bound by any notice or demand, or any waiver, modification, termination
or rescission of this Agreement unless evidenced by a writing delivered to the Escrow Agent signed by the proper party or parties
and, if the duties or rights of the Escrow Agent are affected, unless it shall have given its prior written consent thereto.

 

5.2 Indemnification.
Subject to Section 5.8 below, the Escrow Agent shall be indemnified and held harmless by the Company from and against any expenses,
including reasonable counsel fees and disbursements, or loss suffered by the Escrow Agent in connection with any action, suit
or other proceeding involving any claim which in any way, directly or indirectly, arises out of or relates to this Agreement,
the services of the Escrow Agent hereunder, or the Escrow Shares held by it hereunder, other than expenses or losses arising from
the gross negligence, fraud or willful misconduct of the Escrow Agent. Promptly after the receipt by the Escrow Agent of notice
of any demand or claim or the commencement of any action, suit or proceeding, the Escrow Agent shall notify the other parties
hereto in writing. In the event of the receipt of such notice, the Escrow Agent, in its sole discretion, may commence an action
in the nature of interpleader in an appropriate court to determine ownership or disposition of the Escrow Shares or it may deposit
the Escrow Shares with the clerk of any appropriate court or it may retain the Escrow Shares pending receipt of a final, non-appealable
order of a court having jurisdiction over all of the parties hereto directing to whom and under what circumstances the Escrow
Shares are to be disbursed and delivered. The provisions of this Section 5.2 shall survive in the event the Escrow Agent resigns
or is discharged pursuant to Sections 5.5 or 5.6 below.

 

5.3 Compensation.
Subject to Section 5.8 below, the Escrow Agent shall be entitled to reasonable compensation from the Company for all services
rendered by it hereunder. The Escrow Agent shall also be entitled to reimbursement from the Company for all reasonable expenses
paid or incurred by it in the administration of its duties hereunder including, but not limited to, all counsel, advisors’
and agents’ fees and disbursements and all taxes or other governmental charges.

 

5.4 Further
Assurances. From time to time on and after the date hereof, the Company and the Founders shall deliver or cause to be delivered
to the Escrow Agent such further documents and instruments and shall do or cause to be done such further acts as the Escrow Agent
shall reasonably request to carry out more effectively the provisions and purposes of this Agreement, to evidence compliance herewith
or to assure itself that it is protected in acting hereunder.

 

5.5 Resignation.
The Escrow Agent may resign at any time and be discharged from its duties as escrow agent hereunder by its giving the other parties
hereto written notice and such resignation shall become effective as hereinafter provided. Such resignation shall become effective
at such time that the Escrow Agent shall turn the Escrow Shares over to a successor escrow agent appointed by the Company and
approved by the Representative, which approval will not be unreasonably withheld, conditioned or delayed. If no new escrow agent
is so appointed within the 60-day period following the giving of such notice of resignation, the Escrow Agent may deposit the
Escrow Shares with any court it reasonably deems appropriate in the State of New York.

 

5.6 Discharge
of Escrow Agent. The Escrow Agent shall resign and be discharged from its duties as escrow agent hereunder if so requested
in writing at any time by all of the other parties hereto; provided, however, that such resignation shall become effective only
upon the appointment of a successor escrow agent selected by the Company and approved by the Representative, which approval will
not be unreasonably withheld, conditioned or delayed.

 

    	 	3	 

     

    

 

5.7 Liability.
Notwithstanding anything herein to the contrary, the Escrow Agent shall not be relieved from liability hereunder for its own gross
negligence, fraud or willful misconduct.

 

5.8 Waiver.
The Escrow Agent hereby waives any right of set-off or any other right, title, interest or claim of any kind (“Claim”)
in, or to any distribution of, the Trust Account and hereby agrees not to seek recourse, reimbursement, payment or satisfaction
for any Claim against the Trust Account for any reason whatsoever.

 

6. Miscellaneous.

 

6.1 Governing
Law. This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of New York,
without giving effect to conflicts of law principles that would result in the application of the substantive laws of another jurisdiction.
The parties hereto consent to the jurisdiction and venue of any state or federal court located in the City of New York, Borough
of Manhattan, for purposes of resolving any disputes hereunder. As to any claim, cross-claim, or counterclaim in any way relating
to this Agreement, each party waives the right to trial by jury.

 

6.2 Third Party Beneficiaries.
Each of the parties to this Agreement hereby acknowledges that the Representative is a third party beneficiary of this Agreement
and this Agreement may not be modified or changed without the prior written consent of the Representative.

 

6.3 Entire
Agreement. This Agreement contains the entire agreement of the parties hereto with respect to the subject matter hereof and,
except as expressly provided herein, may only be changed, amended, or modified by a writing signed by each of the parties
hereto.

 

6.4 Headings.
The headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation
thereof.

 

6.5 Binding
Effect. This Agreement shall be binding upon and inure to the benefit of the respective parties hereto and their legal representatives,
successors and assigns.

 

6.6 Notices.
Any notice, consent or request to be given in connection with any of the terms or provisions of this Agreement shall be in writing
and shall be sent by express mail or similar private courier service, by certified mail (return receipt requested), by hand delivery,
by email or by facsimile transmission:

 

If
to the Company, to:

 

Viveon
Health Acquisition Corp

c/o Gibson, Deal & Fletcher, PC

Spalding Exchange

3953 Holcomb Bridge Road

Suite 200

Norcross Georgia 30092

Attn: Jagi Gill

Email: jgill@viveonhealth.com

 

If
to a Founder, to his/her/its address set forth in Exhibit A.

 

and
if to the Escrow Agent, to:

 

Continental
Stock Transfer & Trust Company

1
State Street, 30th Floor

New
York, New York 10004

Attn:
Client Administration Dept.

Email:
accountadmin@continentalstock.com

 

    	 	4	 

     

    

 

A
copy of any notice sent hereunder shall be sent to:

 

Chardan
Capital Markets, LLC

17 State Street, Suite 2100

New York, NY 10004

Attn: George Kaufman

Email: gkaufman@chardancm.com

 

with
a copy to:

 

White& Williams LLP

7 Times Square, Suite 2900

New York, NY 10036-6524

Attn: Alexandria E. Kane

Fax No.: (212) 868-4844

Email: kanea@whiteandwilliams.com

 

and:

 

Loeb& Loeb LLP

345 Park Avenue

New York, NY 10154

Attn: Mitchell S. Nussbaum

Fax No.: (212) 407-4990

Email: mnussbaum@loeb.com

 

The
parties may change the persons and addresses to which the notices or other communications are to be sent by giving written notice
to any such change in the manner provided herein for giving notice.

 

6.7 Liquidation
of the Trust Account. The Company shall give the Escrow Agent written notification of the liquidation of the Trust Account
in the event that the Company fails to consummate a Business Combination within the time period specified in the Company’s
Amended and Restated Certificate of Incorporation, as the same may be amended from time to time.

 

6.8 Counterparts.
This Agreement may be executed in several counterparts, each one of which shall constitute an original and may be delivered by
facsimile transmission and together shall constitute one instrument.

 

[Signature
Page Follows]

 

    	 	5	 

     

    

 

WITNESS
the execution of this Agreement as of the date first above written.

 

 

	 	VIVEON HEALTH ACQUISITION CORP.
	 	 
	 	By:	/s/
Jagi Gill
	 	Name:	Jagi Gill
	 	Title:	Chief Executive Officer
	 	 
	 	CONTINENTAL STOCK TRANSFER & TRUST COMPANY 
	 	 
	 	By:	/s/
Ana Gois
	 	Name:	Ana Gois
	 	Title:	Vice President

 

	 	FOUNDERS:
	 	 	 
	 	VIVEON HEALTH LLC
	 	 	 
	 	By:	/s/
Romilos Papadopoulos
	 	 	Name: Romilos Papadopoulos
	 	 	Title: Managing Member

 

[Signature
Page to Stock Escrow Agreement]

 

    	 	6	 

     

    

 

EXHIBIT
A

 

	Name and Address of Founder	 	Number of Shares	 
	Viveon Health LLC	 	 	   	 
	 	 	 	5,031,250

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00318-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00318-of-00352.parquet"}]]